Practice

Global Data Show Variety in Adalimumab Biosimilar Design, Patient Support Systems

November 7th 2025

By Skylar Jeremias

New findings explore the adalimumab biosimilar landscape, focusing on formulation, devices, and patient support programs that enhance treatment experiences.

UK Experts Publish Guidance on JC Virus Testing for Natalizumab Biosimilar Tyruko

November 5th 2025

By Skylar Jeremias

UK neurologists release new guidelines for JC virus testing in patients using the natalizumab biosimilar Tyruko, addressing safety and monitoring challenges.

Biosimilars Improve Health System Resilience in Latin American, Caribbean Nations

October 28th 2025

By Skylar Jeremias

Biosimilars revolutionize health care access in Latin America, offering cost savings and improved treatment availability for chronic conditions and oncology.

Real-World Stability Confirmed for Biosimilar Ximluci in Prefilled Syringes

October 9th 2025

By Skylar Jeremias

A recent study confirms the stability of XSB-001 biosimilar for retinal diseases under realistic clinical handling conditions.

Review Identifies Gaps in Evidence on Biosimilar DMARD Use During Pregnancy

October 9th 2025

By Skylar Jeremias

A review of the safety of biosimilar DMARDs during pregnancy reveals critical evidence gaps and the need for informed clinical guidance.

Inpatient Biosimilar Use Grows, Offering Cost-Saving Opportunities for Health Systems

July 11th 2025

By Aislinn Antrim

Consumers and Providers Face Biosimilar Knowledge Hurdles

July 7th 2025

By Skylar Jeremias

Significant knowledge gaps about biosimilars persist among consumers and healthcare professionals, hindering their adoption and potential benefits in health care.

Adalimumab Double Take: The Unexpected Return to Reference Humira

June 30th 2025

By Skylar Jeremias

About 13% of patients who switch from Humira to an adalimumab biosimilar switch back to the originator, according to research from Truveta. However, the presented data may not tell the full story.

Increasing Biosimilar Use Reflects Changing Practice in Pediatric IBD Care

June 25th 2025

By Skylar Jeremias

Pediatric infliximab biosimilar use has risen significantly, reflecting evolving treatment patterns in inflammatory bowel disease (IBD) among children and young adults.

European Data Confirm Real-World Benefits of Adalimumab Biosimilars

June 11th 2025

By Skylar Jeremias

New research highlights the efficacy and high patient satisfaction of adalimumab biosimilars in treating inflammatory diseases.